 Research leaves its mark



 65th anniversary



**Cancer
Research
Society**

Help our researchers find a cure

MISSION

Founded in 1945, the Cancer Research Society (CRS) is a national not-for-profit organization whose sole mission is to fund cancer research exclusively and to offer seed money to the most promising original ideas, projects and researchers across Canada.

VISION

For 65 years, the CRS has worked tirelessly toward one goal and one hope: defeating cancer.

HISTORY OF THE CANCER RESEARCH SOCIETY

The CRS is the first Canadian organization whose sole purpose is to fund cancer research. Since its founding in 1945, it has been helping Canadian researchers and physicians to better understand the causes of cancer. The CRS contributes to the development of effective treatments that improve patients' quality of life and helps to protect Canadians' health through cancer prevention.

For more than six decades, the CRS has continued to fulfill its mission by awarding research grants and fellowships, and funding strategic scientific initiatives across Canada.



TABLE OF CONTENTS

Mission - Vision - History.....	2
Table of contents.....	3
Message from the President of the Board of Directors	4
Message from the Executive Director	5
Research and development	
Key facts about cancer.....	6
A look at some of our Canadian researchers.....	7 - 8
Environment-Cancer Fund™	9
Fundraising activities.....	10 - 11
Financial activities.....	12 - 13
Board of Directors.....	14
Scientific partners.....	14
Donors.....	15



MESSAGE FROM THE PRESIDENT OF THE BOARD OF DIRECTORS

Our mission: funding the most innovative and promising projects

When considering cancer, we can never adequately convey the fundamental role of research in the fight against the over 200 types of this insidious disease that has the ability to mutate, adapt and evolve over time. Investing in the most promising research projects is therefore critical, and a stepping stone towards important progress: each day, we are learning more about how cancer develops.



This perspective underlies the decision of the Cancer Research Society (CRS) to work with its partners in order to primarily grant start-up funds to innovative projects. In 2009-2010, for example, a total of over \$5.6 million was allocated to Canadian researchers. Their work has culminated (and will continue to do so) in the discovery of novel concepts that can lead to new means of treating, stopping the growth of, and even curing certain types of cancers.

It is particularly interesting to note that the quality of the funding applications we receive has risen over the past few years, with Canadian researchers putting forth original and scientifically sound ideas: in the last year alone, nearly 40% of the applications submitted would have been eligible for funding. This being said, the difficult economic situation that prevailed over the past year limited us to funding only 28, or 36%, of all scientifically eligible applications. These numbers are far too low. We must make even greater efforts to support the critical projects of our talented researchers.

Striving to stay ahead of the game: research in the field of environment-cancer

In an initiative to break new ground in the fight against cancer, the CRS created the Environment-Cancer Fund™ in 2006. According to an article published in *Pharmaceutical Research* (volume 25, number 9, 2097-2116), it is believed that environmental causes could be responsible for up to 90% of all cancers. It is thus imperative that our efforts include a focus on this field of research: from 2006 to 2009, we honoured our commitments in this regard by funding a total of three environment-cancer projects. Moreover, four new projects have been announced for the coming year. The last fiscal year also saw the official announcement of a major partnership with the Québec government in the field of environment-cancer, an initiative that we hope will be replicated elsewhere in Canada. At the same time, the work carried out by Dr. Jack Siemiatycki's team, of the Guzzo Environment-Cancer Research Chair of the Cancer Research Society in partnership with the Université de Montréal, was particularly impressive this year: thus far, seven articles have been published and the team participated in seven different conferences. I would specifically like to emphasize the group's research in the area of lung cancer and the environment, as well as its findings on the effects of alcohol consumption on cancer. The scientific breakthroughs emanating from this research are promising. They encourage us to continue our work in this field dedicated to better understanding the detrimental effects of certain environments and lifestyle habits on our health.

Thanks to the innovative projects carried out by our researchers and the ongoing support of our partners and donors, the CRS can continue its mission and its funding of research. All this is with a single goal in mind: defeating cancer!

A handwritten signature in black ink that reads "Mario Chevette".

Mario Chevette, PhD

MESSAGE FROM THE EXECUTIVE DIRECTOR

Encouraging financial results that hold promise for the future

The Cancer Research Society's 2009-2010 annual report gives me the occasion to make a positive assessment of the fiscal year that has just ended. It is an opportune moment to underscore the exceptional efforts of all the employees and volunteers of the Cancer Research Society (CRS) and to extend our thanks to our donors for their generous support.

In addition to these encouraging results, it bears noting that the CRS is today reaping the rewards of having opted for a prudent approach and sound strategies in response to the economic challenges of the last few years. The guidelines we established last year focused on general cost reductions, tighter administrative controls, and the development of more efficient and profitable internal policies with regard to fundraising. Certain revenue diversification initiatives, notably the creation of the CRS Challenge and the redesign of our website to facilitate online contributions by donors, generated tangible results.

All of these measures allowed the CRS to maintain high standards in the area of sound management, as well as to deliver encouraging financial results that hold promise for the future.

A vision for the long term

CRS is able to plan its cancer research funding over the long term because it has been honing its expertise in this regard since the organization was founded in 1945. The CRS was established 65 years ago, when it undertook its mission of exclusively funding scientific research projects to support the fight against cancer. We are optimistic as we celebrate our organization's 65th anniversary this year. Firmly focused on the future, the CRS has every right to be proud of its history of achievements.

Such a long tenure would not have been possible without the benevolent support of our donors, the innovative projects carried out by our researchers, and the dedication of our numerous partners and volunteers. We have endeavoured to diversify our partnerships through the signing of new cause-related marketing agreements, the creation of targeted funds, and the development of institutional alliances that have enabled us to expand our financial portfolio of research funds to encompass various types of cancer.

One of our core initiatives in 2009-2010 was the update of the CRS website. This time- and energy-intensive project resulted in the development of a tool that now makes it possible to meet several critical scientific research and fundraising requirements: in addition to accepting online donations, our new website also allows us to continually enhance our virtual portal of fundraising activities and cancer research information and reference tools.

Upcoming challenges

In closing, I would like to once again mention our mission as well as the challenges we will soon be facing. The Statistics Canada report on cancer survival rates published this year indicates an overall upward trend across the country. This encouraging information is due, among other things, to the role of research in enabling the development of increasingly personalized medicine and therapy that is better targeted to the individual. While positive overall, the report nonetheless illustrates the limited scientific progress made for certain types of cancers, these often being the ones which are less funded and hence the focus of fewer research initiatives. For this reason, we are more determined than ever to pursue our efforts vis-à-vis cancer research. Statistics Canada estimates the new cancer cases in Canada in 2010 at approximately 173,800, and posits that one out of every four Canadians will die from cancer. We are obviously far from having beaten this disease. The challenges that await our researchers are significant, and their mission critical.

Let us join together to help our researchers find a cure!



Andy Chabot



RESEARCH & DEVELOPMENT



KEY FACTS ABOUT CANCER: FIGURES THAT GIVE US HOPE

Statistics Canada estimates that in 2010, there will be an average of 20 new instances of cancer and 8 cancer-related deaths in Canada each hour of each day, or 173,800 new cancer cases and 76,200 deaths for the year as a whole. This predicted rise in the number of cancer diagnoses is mostly due to demographic growth and the aging of the population.

This being said...

- The overall cancer rate among men over the age of 69 is dropping, primarily because of a decrease in new lung cancer cases, a phenomenon associated to dwindling tobacco use among the general population. Lung cancer, however, remains the leading cause of death for both men and women.
- The mortality rate is nonetheless dropping among men in most age groups, as well as among women under the age of 70.
- If we exclude lung cancer, the overall mortality rate due to cancer among women has dropped by nearly 20% since 1981.
- While over half of the new cases of breast cancer occur in women between the ages of 50 and 60, there will be more deaths from breast cancer among women aged 80 or more. This is an indication that screening and therapy are enabling middle-aged women to live longer.
- Most cases of prostate cancer will occur in men between the ages of 60 and 69. This being said, deaths due to prostate cancer are more numerous among men aged 80 or more. These figures presumably attest to the benefits of screening for men in their sixties as well as to the disease's slow progression in a large number of cases.
- Statistics Canada has published comparative data on cancer survival rates for persons diagnosed between 1992 and 1994 and those diagnosed between 2004 and 2006. There is good news: study results indicate that cancer survival rates have continued to rise in Canada, with the report illustrating that "the five-year relative survival ratio is 62% for all types of cancers combined." These encouraging data are due, among other things, to the role played by research in enabling the development of increasingly *personalized medicine* and *treatment that is better targeted* to the individual.

SOME OF THE YEAR'S NOTABLE PROJECTS

Basic research:

This year, the Cancer Research Society (CRS), in association with its partners, funded a total of 88 research projects.

A look at some of our Canadian researchers...

1. The majority of cancer deaths are due to tumour metastasis, which occurs when cancer cells break off from a primary tumour, enter the bloodstream and move on to invade new tissue, where they form secondary or metastatic tumours. A secondary tumour that develops in a critical organ such as the lungs can disrupt vital functions and eventually cause death.



This year, the CRS has awarded grants to 9 research projects studying metastatic tumours. One of these projects, led by **Dr. Michael Gold** in British Columbia, is seeking to discover why cancer cells have an easier time penetrating blood vessels when white blood cells are present. Because the latter are more prevalent when there is inflammation, Dr. Gold is seeking to determine whether such inflammation contributes to an increase in tumour metastasis and if so, how anti-inflammatory drugs could prove effective in fighting metastasis.

2. In 2010, it is estimated that 4,000 Canadians will be diagnosed with pancreatic cancer and that 3,900 will die from the disease. The survival rate for pancreatic cancer, at a mere 6% five years after the initial diagnosis, ranks among the lowest cancer survival rates, primarily because of the lack of effective treatment.



The CRS is currently funding 3 projects to study pancreatic cancer, including an initiative spearheaded by **Dr. Norman Kneteman** of the University of Alberta. Through his research, Dr. Kneteman is attempting to increase pancreatic cancer cells' sensitivity to the TRAIL anti-cancer molecule. The increased sensitivity of cancer cells will be achieved by changing the expression of certain genes such as cFLIP and RIP. This study could lead to novel therapeutic approaches for more effectively fighting pancreatic cancer and increasing patient survival rates.

● Research leaves its mark

A look at some of our Canadian researchers... continued

- 3.** There are genes, called tumour suppressors, whose role is to battle the development of tumours. In the event of a mutation which has the effect of disabling a tumour suppressor gene, the latter's protective effect will disappear and tumours will develop.



The CRS is currently funding 6 projects to study tumour suppressor genes, among these a study by **Dr. Michael Mowat** of the Manitoba Institute of Cell Biology at the University of Manitoba. Dr. Mowat is using a mouse model where the Dlc tumour suppressor gene is deleted from various tissues or organs in order to determine whether its absence leads to the formation of more aggressive tumours. This mouse model will essentially reproduce the process that occurs in cancer patients.

- 4.** Leukemia is one of the 9 most frequently diagnosed cancers in Canada, and it is estimated that around 4,800 new cases will be identified in 2010. The leukemia survival rate, 5 years after a diagnosis has been made, is 55%.



This year, the CRS has awarded grants to 4 research projects to study leukemia. One of these projects is spearheaded by **Dr. Reginald Gorczynski** of Toronto Hospital, who is studying the relationship between the expression of CD200, the immunosuppressant protein found in the serum of patients with chronic lymphocytic leukemia, and resistance to therapy. Through his research, Dr. Gorczynski hopes to find a method of blocking the action of the CD200 protein to improve leukemia therapy.

- 5.** Severe weight loss, called cachexia, is often observed in persons with various types of cancer, and is a prognostic indicator at all stages of the disease. Cachexia frequently leads to rapid progression of the cancer and is frequently associated with severe malaise, fatigue and anorexia.



This year, the CRS is funding three projects on cancer cachexia, including one led by **Dr. Robert Sladek** of Montréal's McGill University. Dr. Sladek's research focuses on the proteins that cause the metabolic changes in the liver that result in cancer cachexia. By helping us to better understand and prevent cachexia, this study aims to slow down the growth of cancer.

ENVIRONMENT-CANCER FUND™

In 2008, thanks to the Environment-Cancer Fund™, the CRS launched a large-scale project: the Guzzo Environment-Cancer Research Chair of the Cancer Research Society in partnership with the Université de Montréal. This project's research potential is immense, covering the study of various types of cancer as well as a practically unlimited number of substances to which humans are exposed throughout their lives.




The holder of the Environment-Cancer Chair, **Dr. Jack Siemiatycki**, leads a team of colleagues, research assistants and graduate students from the *Centre de recherche du Centre hospitalier de l'Université de Montréal*. They are currently working on the project, "Determining the cancer risks associated with different aspects of our environment."

The team will also be attempting to determine whether excessive alcohol consumption is associated with a higher risk of developing certain types of cancer, such as oesophageal, liver, stomach, colon and prostate cancer.

They are also studying women's hormonal characteristics, to identify whether they can have an impact on the risk of developing lung cancer. The team will also be investigating whether exposure to low levels of asbestos increases the risk of lung cancer and mesothelioma, and is seeking to determine whether women living near asbestos mines are at greater risk. Lastly, the team will study the risks to workers who come into contact with paint and diesel fumes, as well as those exposed to metals such as cadmium, nickel and chromium.

Allocation of funds invested in research for 2009-2010:



FUNDRAISING ACTIVITIES

Each donation counts in our fight against cancer!

The Cancer Research Society (CRS) collects public donations as part of its activities as a charitable organization. This year, hundreds of thousands of donors responded to our appeal by generously supporting the Society's mission. Each donation we receive takes us one step further in our fight against cancer. For over 65 years, the CRS has invested the funds raised where they are deemed most useful, i.e., in the exclusive funding of cancer research.

Events that make all the difference

Fundraising activities are an invaluable source of support for the Cancer Research Society, from both a financial standpoint and a human perspective. In 2009-2010, thanks to the involvement of hundreds of volunteers, nearly 30 fundraising events were held across Canada, enabling us to raise considerable funds in support of cancer research.

A LOOK AT SOME OF OUR EVENTS IN 2009-2010

Golf tournament presented by Uniprix

On August 26, 2010, 144 golfers gathered at the Elm Ridge Golf Club on Île Bizard to take part in the CRS' 17th Annual Golf Classic. Presided by Honorary Chairman **François Castonguay**, **Uniprix President**, the event raised a net amount of **\$147,724** for cancer research.

From left to right: **Domenic Pilla**, **François Castonguay**, **Mario Chevette** and **Andy Chabot**.



Read for the Cure

Since 2006, a reading club has been organizing literary events in Toronto and Ottawa featuring award-winning Random House Canadian authors. In 2009, \$70,000 was raised thanks to this reading club and to date, Read for the Cure has raised a cumulative amount of more than \$125,000 for environment-cancer research. Read for the Cure is a non-profit Canadian volunteer organization that raises money for the CRS.

Organizers of Read for the Cure.

Photograph donated by **Henrietta Haniskova**.

Rob Lutterman Ski for the Cure

On Saturday, March 13, 2010, the 11th edition of the Rob Lutterman Ski for a Cure was held at Mont Sutton and raised \$45,000 for pancreatic cancer research. On July 28th, 1999, Rob Lutterman lost his battle with pancreatic cancer at the age of 63. Shortly after, his family and a group of friends decided to create an annual ski day to raise money for cancer research and to commemorate Rob, who was an avid skier. The Rob Lutterman Memorial Fund for the CRS was created to promote and fund research into pancreatic cancer: a first grant of \$300,000 was awarded to researcher Dr. Norman Kneteman of the University of Alberta. A second grant for the same amount was awarded this past year to researcher Dr. Michel L. Tremblay from McGill University in Montréal.





The first achievement for the CRS Challenge: the Great Wall of China Marathon

The CRS Challenge is a program of fundraising expeditions organized in support of cancer research. The first ever program challenge, the Great Wall of China Marathon, took place in May 2010: this marathon has the reputation of being one of the hardest on the planet. Having survived a rigorous training and motivated by their cancer heroes, our first participants Chrep Lok, Bruno Bernier and André Buteau demonstrated their dedication to the cause by accomplishing their goal at all costs: despite several difficulties, our three participants realized their challenge in under 8 hours. This first activity of the CRS Challenge program raised more than \$30,000 for cancer research.

Step Up for the Cure

Step Up for the Cure is a 24-hour climbing marathon with the objective to climb one stair for each of the estimated 11 million people who are diagnosed with cancer each year. Every step counts, marking one additional step in the fight against cancer. In 2009, the event took place in Montréal on September 26 and raised \$30,000. Since 2007, more than \$150,000 has been raised for the CRS thanks to Step Up for the Cure and its prime organizer Dan Fisher.



Suits for the Cure

In July 2010, the CRS made an agreement with the Canadian clothing manufacturer for men, S. Cohen. In collaboration with the CRS, the company has agreed to fund a cancer research grant on breast cancer for an amount of \$120,000. For each "Suit for the Cure" sold, \$20 will be invested in cancer research.

The CRS wishes to acknowledge the contribution of the following activities' organizers:

ACTIVITIES	CITY	PROVINCE
2 nd Annual Ponsard Reunion Hockey Game	Montréal	Québec
2009 Poker Challenge – Make a bet for life	Throughout Québec	Québec
A. L. Moore Golf Classic 2009	Barrie	Ontario
Centre 16-18 ans	Greenfield Park	Québec
Chicks With Stix	Cambridge	Ontario
Douglas Brian Shapiro Golf Tournament	Pine Hill	Québec
John Sanvido Memorial Golf Tournament	Guelph	Ontario
Lasalle Legion Cancer Reseach Fundraiser	Lasalle	Québec
Les Grandes Gueules et Richard Turcotte	Montréal	Québec
Marjolaine Bazinet Foundation BBQ	St-Hugues-de-Bagot	Québec
McGill University's Desautels MBA 0-week Fundraiser	Montréal	Québec
Rase-o-thon Suzanne Plante	Mansonville	Québec
Soirée Pioneer Lacasse	Lacolle	Québec

FINANCIAL ACTIVITIES

In a relatively difficult context in many respects, the financial results of the Cancer Research Society are considered very satisfactory. The overall fundraising activities witnessed a rate of growth of some 28.2% while costs including administration charges showed a drop of 6.6%.

These results reflect a more targeted approach in our fundraising activities combined with tight cost controls. The excess of revenues over expenses will allow the Cancer Research Society to maintain a solid financial base to meet its research and other commitments in the future.

Financial position As at August 31, 2010

			2010	2009
	General Management Fund \$	Environment- Cancer Fund™ \$	Total \$	Total \$
Assets				
Current assets				
Cash	4,263,701	661,907	4,925,608	1,106,848
Short-term investments	-	-	-	29,605
Marketable securities	10,356,266	-	10,356,266	9,685,731
Accrued interest	66,651	-	66,651	61,668
Amounts receivable	248,228	-	248,228	146,795
Prepaid expenses	1,389,816	-	1,389,816	211,218
Other assets	47,518	-	47,518	40,913
	16,372,180	661,907	17,034,087	11,282,778
Equipment and leasehold improvements	457,472	-	457,472	361,746
	16,829,652	661,907	17,491,559	11,644,524
Liabilities				
Current liabilities				
Accounts payable and accrued liabilities	1,689,126	-	1,689,126	205,452
Deferred contributions	410,979	-	410,979	475,703
	2,100,105	-	2,100,105	681,155
Net Assets				
Net assets invested in equipment	449,648	-	449,648	351,966
Unrestricted net assets before commitments	14,279,899	661,907	14,941,806	10,611,403
	14,729,547	661,907	15,391,454	10,963,369
	16,829,652	661,907	17,491,559	11,644,524



Financial activities
2009-2010

			2010	2009
	General Management Fund \$	Environment- Cancer Fund™ \$	Total \$	Total \$
Revenues				
General Management Funds and Environment-Cancer Funds™				
Donations from public	12,701,536	200	12,701,736	10,301,827
Major and planned gifts	1,868,513	-	1,868,513	1,356,180
Commemorative donations	238,194	-	238,194	214,917
Fundraising projects	913,918	294,366	1,208,284	756,084
Investment income	400,832	-	400,832	224,476
Partnerships	1,207,357	200,000	1,407,357	1,050,355
	<u>17,330,350</u>	<u>494,566</u>	<u>17,824,916</u>	<u>13,903,839</u>
Expenses				
Programs				
Research grants	5,513,909	160,000	5,673,909	6,683,410
Administration	1,169,797	140,837	1,310,634	1,453,486
	<u>6,683,706</u>	<u>300,837</u>	<u>6,984,543</u>	<u>8,136,896</u>
Campaign expenses	6,129,543	1,021	6,130,564	6,518,329
	<u>12,813,249</u>	<u>301,858</u>	<u>13,115,107</u>	<u>14,655,225</u>
Excess (of expenses over revenues) of revenues over expenses before amortization after research grants	4,517,101	192,708	4,709,809	(751,386)
Amortization of equipment and of leasehold improvements	71,388	-	71,388	71,683
Excess (of expenses over revenues) of revenues over expenses after research grants	<u>4,445,713</u>	<u>192,708</u>	<u>4,638,421</u>	<u>(823,069)</u>

Certain comparative figures have been reclassified to conform to the financial statement presentation adopted in the current year.

BOARD OF DIRECTORS

Mario Chevrette, President
Researcher & Professor, McGill University

Annick Bergeron, Vice-President
Lawyer, Director of Legal Affairs
Université de Montréal

Micheline Bouchard, Secretary
Lawyer, Loranger, Marcoux g.p.

Nathalie Labelle, Treasurer
Partner, Chartered Accountant, KPMG

Michel G. Bouchard, Director
Partner, Cheverny Capital

Marie-Kym Brisson, Director
Vice-President, Public Affairs and
Communications, Génome Québec

François Des Rochers, Director
Director, Market development,
Information Systems, Alogient

Lucie Jeannotte, Director
Professor, Centre de recherche en cancérologie
de l'Université Laval

Heidi Lange, Director
President, Lange Consulting Inc.

Gail C. Snyder, Director
Communications and Marketing Consultant

Denis Soulières, Director
Physician, Hôpital Notre-Dame

Richard M. Wise, Director
Managing Partner, Wise, Blackman LLP

SCIENTIFIC PARTNERS

Each year, the Cancer Research Society (CRS) funds educational institutions, research centers, hospitals, foundations and alliances through its fellowships and strategic & operational grants, in both basic and environment-cancer research.

Here is the list of organizations which have benefited from CRS funding:

British Columbia Cancer Agency, Vancouver, British Columbia
Centre de recherche de l'Hôtel-Dieu de Québec, Québec, Québec
Centre de recherche du CHUL (CHUQ), Québec, Québec
Centre de recherche du CHUM (CRCHUM), Montréal, Québec
Centre hospitalier de l'Université de Sherbrooke, Sherbrooke, Québec
Centre hospitalier de l'Université Laval (CHUL), Québec, Québec
CHU Sainte-Justine Research Center, Montréal, Québec
Hôpital Maisonneuve-Rosemont, Montréal, Québec
Hôpital Notre-Dame du CHUM, Montréal, Québec
Hôtel-Dieu de Montréal, Montréal, Québec
Hôtel-Dieu de Québec, Québec, Québec
Institut de recherches cliniques de Montréal, Montréal, Québec
Jack Bell Research Centre, Vancouver, British Columbia
McGill University Health Centre, Montréal, Québec
McGill University, Montréal, Québec
McMaster University, Hamilton, Ontario
Memorial University of Newfoundland, St. John's, Newfoundland
Montreal General Hospital, Montréal, Québec
Mount Sinai Hospital, Toronto, Ontario
Ottawa Health Research Institute, Ottawa, Ontario
Queen's University, Kingston, Ontario
Sunnybrook Research Institute, Toronto, Ontario
The Hospital for Sick Children, Toronto, Ontario
Université de Montréal, Montréal, Québec
Université de Sherbrooke, Sherbrooke, Québec
Université du Québec à Montréal (UQAM), Montréal, Québec
University Health Network, Toronto, Ontario
University of Alberta, Calgary, Alberta
University of British Columbia, Vancouver, British Columbia
University of Calgary, Calgary, Alberta
University of Guelph, Guelph, Ontario
University of Manitoba, Winnipeg, Manitoba
University of Ottawa, Ottawa, Ontario
University of Toronto, Toronto, Ontario
University of Victoria, Victoria, British Columbia
University of Western Ontario, London, Ontario
University of Windsor, Windsor, Ontario
Vancouver Hospital & Health Sciences Centre,
Vancouver, British Columbia



DONORS

The Cancer Research Society (CRS) truly appreciates the support obtained from the businesses, foundations, employee committees and other organizations involved in the fight against cancer. We would like to thank the 230,000 donors who enable the CRS to support cancer research.

\$100,000 and more

BMO MasterCard
Fonds de la recherche
en santé du Québec
Guzzo Cinemas
Rio Tinto Alcan

From \$25,000 to \$99,999

Anonymous
Bergeron-Jetté Foundation
CN Employees' and
Pensioners' Community
Fund
McKesson Canada
Read for the Cure
Rita Steinberg Goldfarb
Foundation
Rob Lutterman Ski for
a Cure
Step Up for the Cure
Uniprix Group

From \$10,000 to \$24,999

2009 Poker Challenge: Make
a Bet for Life
Andy Chabot Fund
CanadaHelps.org
Consortia
Création Paul H.
John Sanvido Memorial Golf
Tournament
Marjolaine-Bazinet
Foundation BBQ
Pepsi
Strategic Charitable Giving
Foundation
The Jewish Community
Foundation of Montreal

From \$5,000 to \$9,999

Apotex
Bell Canada
BMO Employee Charitable
Foundation
Brickmill Marketing Services
CGI
Chicks with Stix
Dunton Rainville
EssOR Insurance-
Investment-Counselling
Freedom 55 Financial
Imperial Popcorn
Investissement
Guy Locas inc.
Investissement Québec
Laboratory Du-Var Inc.
Le Château
Ogilvy Renault
ratiopharm
Sandoz Canada
SMi
Teva Canada
The Charles Norcliffe Baker
& Thelma Scott Baker
Foundation
The Great-West Life
Assurance Company
Vortex Solution

Wellington Laboratories Inc.
Yvon Michel Group

From \$1,000 to \$4,999

152245 Canada inc.
171909 Canada inc.
2nd Annual Ponsard Reunion
Hockey Game
4165373 Canada inc.
91304717 Québec inc.
A. & D. Prévost Inc.
A. L. Moore Golf Classic
AECOM Tecult
Alliance Atlantis Vivafilm
Aqua Spa Lyne Giroux inc.
Artcom
Association Sociale et
Culturelle de Matrice
Associazione Santa Fortunata
ATCO Gas Employee
Community Service Fund
AutoSkin
Axor
Beauchemin Communication
Marketing inc.
Blain Joyal Charbonneau
Compatables agréées
s.e.n.c.r.l.
BMO Nesbitt Burns
BPR
Bristol-Myers Squibb Canada
Canada Post
Canaropa
Cargill Limited
Carlyle & Associates
Carpian Consultants Inc.
Centre 16-18 ans
Centre Dentaire Carré
Léonard Labelle et Associés
Chanel Inc.
CIBC Wood Gundy
Club Optimiste Melocheville
Congrégation des Filles de la
Providence
Crescent Commercial
Corporation
Cucciniello Calandriello
Czybo Investments Inc.
Dayus Register & Grille Inc.
Déneigement S.R.
Desautels MBA 0-Week
Fundraiser
Desdowd Inc.
Desjardins Card Services
Desjardins Centre Financier
aux Entreprises de l'Est de
Montréal
Desjardins General Insurance
Dessau inc.
Dic Ann's
Dic Ann's Foundation
Dorel Industries Inc.
Douglas Shapiro Memorial
Fund
Dr. Erwin Chao Medical
Prof. Corp.
EnCana Cares Foundation

Equinox Industries
Euro-Pharm International
Canada Inc.
Fasken Martineau
Dumoulin LLP
Ferrari Québec
Fidelity Investments
Canada Ltd.
Fiesta Tents Ltd.
Film Service Supérieur inc.
Fondation Denise et Robert
Gibelleau
Fondation Hormisdas Pilon
Fondation Pain & Espoir
Fondation Sibylla Hesse
Garnier Construction Ltd.
Gestion André Waechter
Gestion Dumel inc.
Gestion SoplaJoey inc.
GML Mechanical Ltd.
Griva-Pete Holdings Inc.
Groupe Enxium inc.
Groupe IBI/DAA
Groupe Parim inc.
Groupe Ressources Des
Moulines
Harvest Foundation
HBOC Society of Alberta
Hershey Canada Inc.
Hoco Ltd.
Hydro-Québec
IMS Health
Industrial Alliance Insurance
and Financial Services Inc.
Interpaving Limited
Jamp Pharma Corporation
Janssen-Ortho Inc.
Jean-Paul Beaudry Ltée
John Warren Imports Inc.
Kanner Westmount Inc.
Kaufmann De Suisse Jewelers
KPMG LLP
La Capitale Cosmo Roselli
La Cie d'Éclairage Union
La Sirène De La Mer
Restaurant Poissonnerie
Lasalle Legion Canada
Reseach Fundraiser
Lavoie & Masciotra
Les Centres D'Achats
Beauward Ltée
Les Filles de Jésus
Les Films Seville / EOne
entertainment
Leslie & Irene Dubé
Foundation
Les Pavages Tallarita
Canada inc.
Les Pavés Futurs
Les Productions Feeling inc.
Liberty Sites Ltd.
Logistik Unicorp Inc.
Londono Realty Group
Lorenzo Steel Inc.
Loto-Québec
Louis Vuitton
Marchand Melançon Forget

Marché Central (Bentall LP)
Mécanique Ron Toohey inc.
Merck Frosst Canada Ltd.
Mersynergy Charitable
Foundation
Modico Canada
MPA Gestion Financière inc.
National Bank Financial
Group
Nightclub 54
Parasuco Jeans
Pharmapar
Pharmascience
PitneyBowes Canada Ltd.
PricewaterhouseCoopers
Primolio Sales Inc.
Prisma Construction
Pro Locksmiths Ltd.
Proprio Direct
Province of Manitoba All
Charities Campaign
Qualité Pro Conseils inc.
Quebec's Casinos
Quincaillerie Demers inc.
Rase-o-thon Suzanne Plante
RBC Foundation
RCR International inc.
Richelieu Hosiery Intl Inc.
Robic LLP
Rubino Shoes
Saputo inc.
Schwartz Levitsky
Feldman LLP
Scotiabank
Signature Bachand
S.M. Group International
Sœurs des Saints Noms de
Jésus et de Marie
Soirée d'appréciation Pioneer
Lacasse
Standard Life Assurance
Company of Canada
Starnino Mostovac LLP
St-Lambert Games
TD Waterhouse-Private
Giving Foundation
Telus
The CSL Group Inc.
The Evelyn Steinberg
Alexander Family
Foundation
The John Brouwer
Foundation
The Reformed Mennonite
Church
Tribute Magazine
Universal Studios
Canada Inc.
Université de Montréal
Vasco
Via Rail Canada Inc.
W D Latimer Co. Ltd.
Westwood Mechanical Inc.
Wilson Machine
Zone 3 XXVII Inc

PUBLISHED BY

Communications and Marketing
Cancer Research Society
625 President-Kennedy Avenue, Suite 402
Montréal, QC H3A 3S5

Telephone: 514 861-9227
Toll-free: 1 888 766-2262
www.CancerResearchSociety.ca

Graphic design: Prétex-te Communications
Print production: Au Point-Reprotech

ISSN 1920-9029
Legal deposit – Bibliothèque nationale du Québec, 2010
Legal deposit – Library and Archives Canada, 2010

Printed in Canada

